CHF-6366

• UNSPSC Description:

  CHF-6366 is a potent M3 muscarinic antagonist and β2-adrenergic receptors agonist with pKi values of 10.4 and 11.4, respectively. CHF-6366 is also a weak calcium channel inhibitor (IC50~50 μM). CHF-6366 inhibits bronchoconstriction in guinea pigs. CHF-6366 can be used to research chronic obstructive pulmonary disease (COPD)[1].

• Target Antigen:

  Adrenergic Receptor; Calcium Channel; mAChR

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Membrane Transporter/Ion Channel;Neuronal Signaling

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Endocrinology; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/chf-6366.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(C1=NN(C)C(COC2=CC=CC([C@H](C3=CC=CC=C3)NC(O[C@H]4CN5CCC4CC5)=O)=C2)=C1)OCCCCNC[C@H](O)C6=CC=C(O)C7=C6C=CC(N7)=O

• Molecular Weight:

  764.87

• References & Citations:

  [1]Carzaniga L, et al. Discovery of Clinical Candidate CHF-6366: A Novel Super-soft Dual Pharmacology Muscarinic Antagonist and β2 Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases. J Med Chem. 2022 Aug 11;65(15):10233-10250.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 2

• CAS Number:

  1615208-41-7